iCell® GlutaNeurons Kit, 01279

Glutamatergic neurons derived from human iPS cells, frozen

More Views

From: 595 USD


* Required Fields

Catalog # (Select a product)
Glutamatergic neurons derived from human iPS cells, frozen
From: 595 USD

Required Products


Understanding basic neuronal physiology and discovering therapeutics to treat neurological disorders has relied heavily on rodent primary cell cultures and animal models. These systems have significant drawbacks in terms of biological relevance, reproducibility, and scalability. iCell® GlutaNeurons provide a relevant, excitatory neuronal model that enables researchers to study human neuronal network development and activity through interrogation and manipulation of relevant pathological pathways involved in seizurogenic and neurodegenerative conditions, thereby providing a new and valuable tool for drug discovery, toxicity testing, and basic research.

iCell® GlutaNeurons, human glutamatergic-enriched cortical neurons derived from induced pluripotent stem (iPS) cells, display typical physiological characteristics and form functional neuronal networks amenable to examination across a number of commonly used assays. These cells providing the following:

• Fully differentiated, ≥ 90% pure population of primarily glutamatergic (excitatory) human neurons
• Long-term viability, demonstrated reproducibility, and availability in commercial quantities
• Rapid formation of excitatory neural networks and functional synapses
• Expression of relevant neurological therapeutic targets and pathways
• Compatible with a wide range of biochemical and cell-based assays including: (1) Cell viability, (2) calcium signaling and (3) neurite outgrowth and retraction
• Electrophysiological applications include: (1) Identification and characterization of network function, (2) higher throughput assessment of compound efficacy for seizure treatment and (3) higher throughput detection of seizurogenic toxicity
• Ease of use - simply thaw and plate

Certain products are only available in select territories. Please contact your local Sales Representative or Product & Scientific Support at for further information.
iCell® GlutaNeurons Kit, 01279, 1 x 10^6 cells (Catalog #R1061)
          iCell® GlutaNeurons, 01279, 1 x 10^6 cells
          iCell® Neural Supplement B, 2 mL
          iCell® Nervous System Supplement, 1 mL    
iCell® GlutaNeurons Kit, 01279, 6 x 10^6 cells (Catalog #R1034)
          iCell® GlutaNeurons, 01279, 6 x 10^6 cells
          iCell® Neural Supplement B, 2 mL
          iCell® Nervous System Supplement, 1 mL
iCell® GlutaNeurons Kit 3 pack, 01279, 3 vials x 1 x 10^6 cells (Catalog #R1116)
          iCell® GlutaNeurons, 01279, 3 vials x 1 x 10^6 cells
          iCell® Neural Supplement B, 2 mL
          iCell® Nervous System Supplement, 1 mL
Cell Type:
Neural Cells, PSC-Derived
Cell and Tissue Source:
Pluripotent Stem Cells
Donor Status:

Scientific Resources

Educational Materials


Product Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Data and Publications


Neurotoxicology 2018 JUL

Human iPSC-derived neuronal models for in vitro neurotoxicity assessment.

A. M. Tukker et al.


Neurotoxicity testing still relies on ethically debated, expensive and time consuming in vivo experiments, which are unsuitable for high-throughput toxicity screening. There is thus a clear need for a rapid in vitro screening strategy that is preferably based on human-derived neurons to circumvent interspecies translation. Recent availability of commercially obtainable human induced pluripotent stem cell (hiPSC)-derived neurons and astrocytes holds great promise in assisting the transition from the current standard of rat primary cortical cultures to an animal-free alternative. We therefore composed several hiPSC-derived neuronal models with different ratios of excitatory and inhibitory neurons in the presence or absence of astrocytes. Using immunofluorescent stainings and multi-well micro-electrode array (mwMEA) recordings we demonstrate that these models form functional neuronal networks that become spontaneously active. The differences in development of spontaneous neuronal activity and bursting behavior as well as spiking patterns between our models confirm the importance of the presence of astrocytes. Preliminary neurotoxicity assessment demonstrates that these cultures can be modulated with known seizurogenic compounds, such as picrotoxin (PTX) and endosulfan, and the neurotoxicant methylmercury (MeHg). However, the chemical-induced effects on different parameters for neuronal activity, such as mean spike rate (MSR) and mean burst rate (MBR), may depend on the ratio of inhibitory and excitatory neurons. Our results thus indicate that hiPSC-derived neuronal models must be carefully designed and characterized prior to large-scale use in neurotoxicity screening.
Stem cell research 2018 APR

The GluN2B subunit represents a major functional determinant of NMDA receptors in human induced pluripotent stem cell-derived cortical neurons.

I. Neagoe et al.


Abnormal signaling pathways mediated by N-methyl-d-aspartate receptors (NMDARs) have been implicated in the pathogenesis of various CNS disorders and have been long considered as promising points of therapeutic intervention. However, few efforts have been previously described concerning evaluation of therapeutic modulators of NMDARs and their downstream pathways in human neurons with endogenous expression of NMDARs. In the present study, we assessed expression, functionality, and subunit composition of endogenous NMDARs in human induced pluripotent stem cell (hiPSC)-derived cortical neurons (iCell Neurons and iCell GlutaNeurons). We initially confirmed the expected pharmacological response of iCell Neurons and iCell GlutaNeurons to NMDA by patch-clamp recordings. Subsequent pharmacological interrogation using GluN2 subunit-selective antagonists revealed the predominance of GluN2B in both iCell Neurons and iCell GlutaNeurons. This observation was also supported by qRT-PCR and Western blot analyses of GluN2 subunit expression as well as pharmacological experiments using positive allosteric modulators with distinct GluN2 subunit selectivity. We conclude that iCell Neurons and iCell GlutaNeurons express functional GluN2B-containing NMDARs and could serve as a valuable system for development and validation of GluN2B-modulating pharmaceutical agents.